FDA capacity forces delay to Iovance's cell therapy

Submitted by admin on September 15, 2023 - 11:47am

Source:

Pharmaphorum

News Tags:

Iovance Biotherapeutics

lifileucel

cell therapy

FDA

melanoma

Headline:

FDA capacity forces delay to Iovance's cell therapy

snippet:

Iovance Biotherapeutics is facing a three-month delay in the review of its lifileucel cell therapy for melanoma in the US, held up by "insufficient resources" at the FDA.

Search form

You are here

FDA capacity forces delay to Iovance's cell therapy

FDA capacity forces delay to Iovance's cell therapy